Lynch G, Magill G B, Sordillo P, Golbey R B
Cancer. 1982 Nov 1;50(9):1724-7. doi: 10.1002/1097-0142(19821101)50:9<1724::aid-cncr2820500912>3.0.co;2-1.
Response rates of metastatic soft part sarcomas to chemotherapy have varied from 27 and 44% for our ALOMAD and OMAD protocols to 46-55% reported for CYVADIC. The present combination, CYOMAD, consists of the induction part of ALOMAD (vincristine, high-dose methotrexate with citrovorum factor rescue, Adriamycin and DTIC) alternating with a condensed version of CYVADIC (cyclophosphamide, vincristine, adriamycin and DTIC). Forty-one patients with advanced soft-part sarcomas were entered on the CYOMAD program of whom 36 were considered evaluable. Complete responses (CR) were seen in four patients had partial (PR) in five patients for a major response rate of 25%. Responders had an overall longer survival than nonresponders (20 versus 13 months). Toxicity was substantial with both gastrointestinal side effects and myelosupression common. Possible Adriamycin cardiotoxicity was noted in four patients. Cyomad offered no therapeutic advantage over previous protocols and was even less well tolerated than some.
转移性软组织肉瘤对化疗的反应率有所不同，我们的ALOMAD和OMAD方案的反应率为27%至44%，而CYVADIC报道的反应率为46% - 55%。目前的联合方案CYOMAD由ALOMAD的诱导部分（长春新碱、大剂量甲氨蝶呤加亚叶酸钙解救、阿霉素和达卡巴嗪）与CYVADIC的简化版本（环磷酰胺、长春新碱、阿霉素和达卡巴嗪）交替组成。41例晚期软组织肉瘤患者进入CYOMAD方案，其中36例被认为可评估。4例患者出现完全缓解（CR），5例患者出现部分缓解（PR），主要缓解率为25%。缓解者的总生存期比未缓解者更长（20个月对13个月）。毒性反应严重，胃肠道副作用和骨髓抑制很常见。4例患者出现可能的阿霉素心脏毒性。CYOMAD与先前的方案相比没有治疗优势，甚至耐受性比一些方案更差。
